BB Biotech AG (XSWX:BION) Retained Earnings : CHF2,348.65 Mil (As of Dec. 2023)

View and export this data going back to 1996. Start your Free Trial

What is BB Biotech AG Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. BB Biotech AG's retained earnings for the quarter that ended in Dec. 2023 was CHF2,348.65 Mil.

BB Biotech AG's quarterly retained earnings declined from Jun. 2023 (CHF2,287.92 Mil) to Sep. 2023 (CHF2,239.53 Mil) but then increased from Sep. 2023 (CHF2,239.53 Mil) to Dec. 2023 (CHF2,348.65 Mil).

BB Biotech AG's annual retained earnings declined from Dec. 2021 (CHF3,281.62 Mil) to Dec. 2022 (CHF2,711.56 Mil) and declined from Dec. 2022 (CHF2,711.56 Mil) to Dec. 2023 (CHF2,348.65 Mil).

BB Biotech AG Retained Earnings Historical Data

The historical data trend for BB Biotech AG's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BB Biotech AG Retained Earnings Chart

BB Biotech AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

3,381.89

3,884.71

3,281.62

2,711.56

2,348.65

BB Biotech AG Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Dec17	Dec18	Dec19	Dec20	Mar21	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															2,711.56	2,301.40	2,287.92	2,239.53	2,348.65

BB Biotech AG Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

BB Biotech AG (XSWX:BION) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

BB Biotech AG (XSWX:BION) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BB Biotech AG (XSWX:BION) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

BIONz:UK BBZA:Germany

Address

Schwertstrasse 6, Schaffhausen, CHE, CH-8200

Website

https://www.bbbiotech.com

BB Biotech AG is a part of the healthcare sector in Switzerland. Its primary activity includes making investments, especially in the biotechnology market and is one of the largest investors in the field of biotechnology. The focus of the investments is on those listed companies that focus on the development and marketing of novel drugs with a clear value for the healthcare system. BB Biotech follows a strategy of carefully screening and selecting biotechnology firms with a long-term time horizon and having established products in the marketplace. Geographically it earns key revenue from the Netherlands.

Executives

Prof. Dr. Mads Krogsgaard Thomsen

Supervisory Board

BB Biotech AG (XSWX:BION) Headlines

No Headlines